ReviewOncoTargets and therapy2022

Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer.

Ilana Schlam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.